Novartis bags a surprise approval for the blood cancer-treating panobinostat

Damian Garde

Going against the advice of its independent experts, the FDA approved ' new cancer drug for patients with particularly deadly forms of multiple myeloma, looking past some serious safety issues and concerns about the drug's supporting data.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS